A case series of aripiprazole augmentation of selective serotonin reuptake inhibitors in treatment-refractory obsessive compulsive disorder

References

• Denys D. Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders. Psychiatr Clin N Am 2006;29:553–84.
   PubMed Web of Science ®Google Scholar
• Stein DJ, Ipser JC, Baldwin DS, Bandelow B. Treatment of obsessive-compulsive disorder. CNS Spectr 2007;12(Suppl 3):28–35.
   Google Scholar
• Ipser JC, Carey P, Dhansay Y, Fakier N, Seedat S, Stein DJ, . Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database Syst Rev (Online) 2006;18:CD005473.
   Google Scholar
• Pallanti S, Quercioli L. Treatment-refractory obsessive-compulsive disorder; Methodological issues, operational definitions and therapeutic lines. Prog Neuropsychopharmacol Biol Psychiatry 2006;30;400–12.
   PubMed Web of Science ®Google Scholar
• Skapinakis P, Papatheodorou T, Mavreas V. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. Eur Neuropsychopharmacol 2007;17:79–93.
   PubMed Web of Science ®Google Scholar
• Matsunaga H, Nagata T, , HayashidaOhya K, Kiriike N, Stein. DJ. A long-term effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. J Clin Psychiatry 2009; 70(6):863–8.
   PubMedGoogle Scholar
• Connor KM, Payne VM, Gadde KM, Zhang W. The use of aripiprazole in obsessive-compulsive disorder; preliminary observations in 8 patients. J Clin Psychiatry 2005;66:49–51.
   PubMed Web of Science ®Google Scholar
• Lai C-H. Aripiprazole treatment in an adolescent patient with chronic motor tic disorder and treatment-resistant obsessive-compulsive disorder. Int J Neuropsychopharmacol 2009;12:1291–3.
   PubMedGoogle Scholar
• Ginsberg DL. Aripiprazole augmentation of clomipramine-refactory obsessive-compulsive disorder. Primary Psychiatry 2007;14:19–21.
   Google Scholar
• Friedman S, Abdallah TA, Oumaya M, Rouillon F, Guelfi JD. Aripiprazole augmentation of clomipramine-refractory obsessive-compulsive disorder. J Clin Psychiatry 2007;68: 972–3.
   PubMedGoogle Scholar
• Pessina E, Albert U, Bogetto F, Maina G. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study. Int Clin Psychopharmacol 2009; 24:265–9.
   PubMed Web of Science ®Google Scholar
• Sarkar R, Klein J, Kruger S. Aripiprazole augmentation in treatment-refractory obsessive-compulsive disorder. Psychopharmacology 2008;197:687–8.
   PubMedGoogle Scholar
• Stroch EA, Lehmkuhl H, Geffken GR, Touchton A, Murphy TK. Aripiprazole augmentation of incomplete treatment response in an adolescent male with obsessive-compulsive disorder. Depress Anxiety 2008;25:172–4.
   PubMedGoogle Scholar
• Yang K-C, Su T-P, Chou Y-H. Effectiveness of aripiprazole in treating obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:585–6.
   PubMedGoogle Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th. Washington, DC: American Psychiatric Association; 1994.
   Google Scholar
• First MB, Spitzer RL, Gibbon M, Williams JB. The Structured Clinical Interview for DSM-IV Axis I Disorders. New York: Biometric Research, New York State Psychiatric Institute; 1997.
   Google Scholar
• Goodman WK, Price L, Rasmussen SA, Mazure C, Fleishmann RL, Hill C, . The Yale-Brown Obsessive-Compulsive Scale, I: development, use, and reliability. Arch Gen Psychiatry 1989;46:1006–11.
   PubMed Web of Science ®Google Scholar
• Goodman WK, Price L, Rasmussen SA, Mazure C, Delgado P, Heninger GR, . The Yale-Brown Obsessive-Compulsive Scale, II: validity. Arch Gen Psychiatry 1989;46:1012–16.
   PubMed Web of Science ®Google Scholar
• Nakajima T, Nakamura M, Taga C, Yamagami S, Kiriike N, Nagata T, . Reliability and validity of the Japanese version of the Yale-Brown Obsessive-Compulsive Scale. Psychiatry Clin Neurosci 1995;49:121–6.
   PubMed Web of Science ®Google Scholar
• Bloch MH, Landeros-Weisenberger A, Rasario MC, Pittenger C, Leckman JF. Meta-analysis of the symptom structure of obsessive-compulsive disorder. Am J Psychiatry 2008;165:1532–42.
   PubMed Web of Science ®Google Scholar
• Denys D, Fineberg N, Carey PD, Stein DJ. Quetiapine addition in obsessive-compulsive disorder: is treatment outcome affected by type and dose of serotonin reuptake inhibitors? Biol Psychiatry 2007;61:412–14.
   PubMed Web of Science ®Google Scholar
• Masi G, Pfanner C, Millepiedi S, Stefano B. Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder. J Clin Psychopharmacol 2010;30:688–93.
   PubMed Web of Science ®Google Scholar
• Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, . Mechanism of action of atypical antipsychotic drugs and neurobiology of schizophrenia. CNS Drugs 2006;20:389–409.
   PubMed Web of Science ®Google Scholar
• Fukui H, Murai T. Severe weight gain induced by combination treatment with risperidone and paroxetine. Clin Neuropharmacol 2002;25:269–71.
   PubMedGoogle Scholar
• Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999;37:177–93.
   PubMed Web of Science ®Google Scholar